1113 / 1851
Is there a role for thoracic RT in ED-SCLC ?
CREST trial
Slotman B. et al. Lancet 2015;385
Overall Survival
OS @ 1 year: 33% vs 28% (p = 0.06)
OS @ 2 years: 13% vs 3% (p = 0.004)
Progression was less likely to occur in
patients treated with thoracic RT
(
PFS @ 6 months = 24% vs 7%, p
= 0.001
)
No differences in grade 3 or higher
toxic effects
Many patients have relapse
outside the thorax and the brain
Thoracic RT
in addition to PCI
should be considered
for all ED-
SCLC patients who respond to
chemotherapy